
The University of New Mexico
NEWS RELEASE
June 26, 2006
Science & Technology Corporation @ UNM Announces Agreements with German Company
The Science & Technology Corporation @ UNM announced today that it has executed three agreements with Berlex, Inc. a U.S. affiliate of Schering AG, Germany, to license and collaborate on the development of drug discovery technology.
STC has granted Berlex a worldwide license to its HyperCyt technology, an automated high-throughput flow cytometry screening analysis system. Moreover, the two organizations entered into agreements to collaborate on two projects to identify therapeutic targets and potential therapeutic drug candidates.
“We are pleased to enter into the arrangement with Berlex, which allows the HyperCyt technology to benefit the public,” says Lisa Kuuttila, President and CEO of STC. “While a discovery based on HyperCyt technology has already led to the formation of one local start-up company, the licensing arrangements with Berlex demonstrate the technology is valuable to larger biopharmaceutical businesses that take laboratory discoveries and develop medical advances for patients,” HyperCyt patent holder and professor of pathology at the University of New Mexico School of Medicine Larry Sklar said. “The match between the interests and expertise at Berlex and UNM promises to make the collaboration exciting with respect to research and economic development.”
The Science and Technology Corporation @ UNM is a nonprofit corporation formed by and owned entirely by the University of New Mexico to protect and transfer its faculty inventions into the commercial marketplace. STC licenses innovative technology developed at UNM, including optics, microfluidics, and high performance materials as well as therapeutics, diagnostics, medical devices and drug discovery tools.
###
www.unm.edu